Gilead purchased a preclinical oncology program targeting TREX1 from Sprint Bioscience, paying an upfront that industry reports place in the low‑double‑digit millions and agreeing to up to $400 million in downstream milestones. The deal reflects Gilead’s continued expansion in oncology and its appetite for early‑stage mechanistic assets. Sprint will receive development and commercial milestones and potential royalties; Gilead will integrate the TREX1 program into its oncology discovery portfolio. The acquisition underscores big‑pharma strategies to outsource early discovery risk while securing promising targets in areas like innate immunity and tumor microenvironment modulation.